Puma Biotechnology Inc (NYSE:PBYI) presented positive results from the Phase II clinical trial of its investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. According to Puma Biotechnology, the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) is a collaborative effort among academic investigators from approximately 20 major cancer research centers across the country, the U.S. Food and Drug Administration, Quantum Leap Healthcare Collaborative, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium including major supporters such as The Safeway Foundation and the Bill Bowes Foundation. Puma Biotechnology Inc (NYSE:PBYI) shares after opening at $80.83 moved to $84.19 on last trade day and at the end of the day closed at $76.17.Company price to cash ratio as 27.34. Puma Biotechnology Inc (NYSE:PBYI) showed a negative weekly performance of -28.42%.
PolyTherics Limited (“PolyTherics”), a provider of technologies and services to enable the development of better biopharmaceuticals, announced an extension to its ThioBridge(TM) antibody drug conjugate (“ADC”) collaboration with MacroGenics Inc (NASDAQ:MGNX), a US biotechnology company developing innovative medicines utilizing its next generation antibody technologies. MacroGenics Inc (NASDAQ:MGNX) shares fell -13.24% in last trading session and ended the day on $20.38. MGNX return on equity ratio is recorded as 32.00% and its return on assets is -8.40%.
Jefferies Group started coverage on shares of Aratana Therapeutics (NASDAQ:PETX) in a research note released on Monday morning,TheFlyOnTheWall.com reports. The firm issued a buy rating and a $25.00 target price on the stock.Aratana Therapeutics Inc (NASDAQ:PETX) shares moved down -7.12% in last trading session and was closed at $13.95, while trading in range of $13.81-$15.06. Aratana Therapeutics Inc (NASDAQ:PETX) year to date performance is -26.96%.
Retrophin, Inc. (NASDAQ:RTRX) announced the completion of acquisition of Manchester Pharmaceuticals LLC for $62.5 million. The Company said that the acquisition adds two FDA approved products to Retrophin including Chenodal, for patients suffering from gallstones whom surgery poses an unacceptable health risk due to disease or advanced age and Vecamyl for the management of moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension.Retrophin Inc (NASDAQ:RTRX) weekly performance is -19.29%. On last trading day company shares ended up $15.36. Retrophin Inc (NASDAQ:RTRX distance from 50-day simple moving average is -10.21%. Analysts mean target price for the company is $51.00.